Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secreta...(ery and provides rapid results in15 minu...),Health

It is estimated that less then 1/3 of those confirmed as being HIV positive in the developing world have access to this critical information and the Inverness CD4 instrument will be the first device to enable low cost CD4 quantification at these point-of-care settings, where the need is greatest.

Clinical trials for the CD4 system will begin in the 4th quarter of this year and the instrument will be launched to select markets in mid-2009. Inverness plans to feature the product at the 15th Annual Conference on AIDS and STIs (ICASA) in Dakar, Senegal December 3-7, 2008.

Ron Zwanziger, President and CEO Inverness Medical Innovations, stated, "We are very pleased with the development progress of the analyzer platform and the broad possibilities for its application across our disease management portfolio. We also realize the immediate significant impact it will have upon the care of those living with HIV in the developing world where few technologies are available at point-of-care."

The Inverness CD4 point-of-care analyzer reflects the commitment by Inverness Medical Innovations to develop and bring to market innovative diagnostics to identify infectious disease and to enable effective health management of those with chronic conditions.

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.
'/>"/>